ATE378064T1 - Verfahren zur behandlung von erkrankungen assoziiert mit akuten entzündung unter nichtischämischen zustände - Google Patents
Verfahren zur behandlung von erkrankungen assoziiert mit akuten entzündung unter nichtischämischen zuständeInfo
- Publication number
- ATE378064T1 ATE378064T1 AT01927646T AT01927646T ATE378064T1 AT E378064 T1 ATE378064 T1 AT E378064T1 AT 01927646 T AT01927646 T AT 01927646T AT 01927646 T AT01927646 T AT 01927646T AT E378064 T1 ATE378064 T1 AT E378064T1
- Authority
- AT
- Austria
- Prior art keywords
- allergic
- ischemic conditions
- diseases associated
- treating diseases
- acute inflammation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Tropical Medicine & Parasitology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20126400P | 2000-05-02 | 2000-05-02 | |
DKPA200001204 | 2000-08-11 | ||
DKPA200001757 | 2000-11-22 | ||
DKPA200100369 | 2001-03-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE378064T1 true ATE378064T1 (de) | 2007-11-15 |
Family
ID=27439821
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01927646T ATE378064T1 (de) | 2000-05-02 | 2001-05-02 | Verfahren zur behandlung von erkrankungen assoziiert mit akuten entzündung unter nichtischämischen zustände |
AT01927645T ATE366116T1 (de) | 2000-05-02 | 2001-05-02 | Verwendung von alpha-msh und epo zur herstellung eines arzneimittels zur prophylaxe oder behandlung von durch ischämischen zuständen bewirkten krankheiten |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01927645T ATE366116T1 (de) | 2000-05-02 | 2001-05-02 | Verwendung von alpha-msh und epo zur herstellung eines arzneimittels zur prophylaxe oder behandlung von durch ischämischen zuständen bewirkten krankheiten |
Country Status (8)
Country | Link |
---|---|
EP (2) | EP1286691B1 (de) |
JP (1) | JP2003531863A (de) |
AT (2) | ATE378064T1 (de) |
AU (4) | AU5462601A (de) |
CA (2) | CA2407785A1 (de) |
DE (2) | DE60131393D1 (de) |
NZ (1) | NZ522851A (de) |
WO (2) | WO2001082952A2 (de) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7410941B1 (en) | 1999-04-13 | 2008-08-12 | The Kenneth S. Warren Institute, Inc. | Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin |
US7345019B1 (en) | 1999-04-13 | 2008-03-18 | The Kenneth S. Warren Institute, Inc. | Modulation of excitable tissue function by peripherally administered erythropoietin |
US7078376B1 (en) | 2000-08-11 | 2006-07-18 | Baxter Healthcare S.A. | Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects |
US6531121B2 (en) | 2000-12-29 | 2003-03-11 | The Kenneth S. Warren Institute, Inc. | Protection and enhancement of erythropoietin-responsive cells, tissues and organs |
DE60313125T2 (de) | 2002-01-09 | 2007-12-20 | Crucell Holland B.V. | Verwendung von erythropoietin zur behandlung oder vorbeugung von herzversagen |
DE10234192B4 (de) | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
AT500929B1 (de) * | 2004-11-09 | 2007-03-15 | Medizinische Uni Wien Muw | Pharmazeutische zubereitung die erythropoietin enthält |
JP2006241043A (ja) * | 2005-03-02 | 2006-09-14 | Kirin Brewery Co Ltd | 炎症性肺疾患の予防及び治療薬 |
EP1919947B1 (de) | 2005-08-26 | 2013-02-27 | AbbVie Inc. | Therapeutisch wirksame alpha-msh-analoga |
WO2007069839A1 (en) * | 2005-12-12 | 2007-06-21 | Kyungpook National University Industry-Academic Cooperation Foundation | Novel use of erythropoietin protein |
AU2007299738B2 (en) | 2006-09-20 | 2013-03-28 | The Board Of Regents Of The University Of Texas System | Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief |
JP5162751B2 (ja) * | 2007-01-17 | 2013-03-13 | 国立大学法人 宮崎大学 | 急性腎不全の検出方法 |
WO2009033812A2 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a combination of neuropeptide-ff and alpha-msh as a therapeutic agent |
AU2008310059A1 (en) * | 2007-09-11 | 2009-04-16 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
EP2190447B1 (de) * | 2007-09-11 | 2012-08-08 | Mondobiotech Laboratories AG | His-Pro-Gly-Ser-Arg-lle-Val-Leu-Ser-Leu-Asp-Val-Pro-lle-Gly-Leu-Leu-Gln-Ile-Leu-Leu-Glu-Gln-Ala-Arg-Ala-Arg-Ala-Ala-Arg-Glu-Gln-Ala-Thr-Thr-Asn-Ala-Arg-ile-Leu-Ala-Arg-Val-NH2 zur Verwendung in der antiangiogenen Therapie |
WO2009094459A1 (en) | 2008-01-22 | 2009-07-30 | The Board Of Regents Of The University Of Texas System | Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief |
CN111150837B (zh) * | 2020-02-11 | 2022-07-12 | 中国人民解放军陆军军医大学 | Epo在抗金黄色葡萄球菌感染药物中的应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3778550D1 (de) * | 1986-08-08 | 1992-05-27 | Univ Texas | Fieber- und entzuendungshemmende peptide. |
DE69531952T2 (de) * | 1994-11-03 | 2004-07-29 | Roche Diagnostics Gmbh | Verwendung des erythropoietins zur behandlung von rheumatoider arthritis |
TW586933B (en) * | 1996-06-20 | 2004-05-11 | Chugai Pharmaceutical Co Ltd | Compositions for treating liver-complaints using EPO |
US20020052309A1 (en) * | 1996-09-11 | 2002-05-02 | Athanasius A. Anagnostou | Method of treating endothelial injury |
IL124015A0 (en) * | 1998-04-08 | 1999-01-26 | Yeda Res & Dev | Pharmaceutical compositions comprising a protein |
-
2001
- 2001-05-02 AT AT01927646T patent/ATE378064T1/de not_active IP Right Cessation
- 2001-05-02 AU AU5462601A patent/AU5462601A/xx active Pending
- 2001-05-02 EP EP01927646A patent/EP1286691B1/de not_active Expired - Lifetime
- 2001-05-02 AU AU2001254625A patent/AU2001254625B2/en not_active Ceased
- 2001-05-02 NZ NZ522851A patent/NZ522851A/en unknown
- 2001-05-02 AT AT01927645T patent/ATE366116T1/de not_active IP Right Cessation
- 2001-05-02 WO PCT/DK2001/000303 patent/WO2001082952A2/en active IP Right Grant
- 2001-05-02 CA CA002407785A patent/CA2407785A1/en not_active Abandoned
- 2001-05-02 WO PCT/DK2001/000304 patent/WO2001082953A2/en active IP Right Grant
- 2001-05-02 AU AU5462501A patent/AU5462501A/xx active Pending
- 2001-05-02 AU AU2001254626A patent/AU2001254626B2/en not_active Ceased
- 2001-05-02 CA CA002407797A patent/CA2407797A1/en not_active Abandoned
- 2001-05-02 JP JP2001579826A patent/JP2003531863A/ja active Pending
- 2001-05-02 DE DE60131393T patent/DE60131393D1/de not_active Expired - Lifetime
- 2001-05-02 DE DE60129221T patent/DE60129221D1/de not_active Expired - Lifetime
- 2001-05-02 EP EP01927645A patent/EP1286690B1/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP1286691B1 (de) | 2007-11-14 |
WO2001082953A3 (en) | 2002-08-01 |
ATE366116T1 (de) | 2007-07-15 |
WO2001082952A2 (en) | 2001-11-08 |
EP1286690B1 (de) | 2007-07-04 |
WO2001082952A3 (en) | 2002-04-18 |
DE60131393D1 (de) | 2007-12-27 |
DE60129221D1 (de) | 2007-08-16 |
AU2001254625B2 (en) | 2006-02-02 |
WO2001082953A2 (en) | 2001-11-08 |
CA2407785A1 (en) | 2001-11-08 |
AU5462601A (en) | 2001-11-12 |
AU2001254626B2 (en) | 2006-09-21 |
CA2407797A1 (en) | 2001-11-08 |
EP1286690A2 (de) | 2003-03-05 |
AU5462501A (en) | 2001-11-12 |
EP1286691A2 (de) | 2003-03-05 |
JP2003531863A (ja) | 2003-10-28 |
NZ522851A (en) | 2004-11-26 |
WO2001082953A8 (en) | 2004-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE378064T1 (de) | Verfahren zur behandlung von erkrankungen assoziiert mit akuten entzündung unter nichtischämischen zustände | |
ATE255896T1 (de) | Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen | |
DE69942702D1 (de) | Zusammenstellungen und methoden zur behandlung der alzheimerschen krankheit, schäden des zentralnervensystems und entzündlichen erkrankungen | |
NO20005887D0 (no) | Forbindelser med IgE-påvirkende egenskaper | |
ATE325612T1 (de) | Verwendung von hydroxyethylrutosiden zur behandlung von erkältungssymptomen, symptomen der allergischen rhinitis und atemwegsinfektionen | |
DE69622894D1 (de) | Substituierte Sulfonylphenylheterocyclen als Cyclooxygenase-2 und 5- Lipoxygenase Inhibitoren | |
DE69831566T2 (de) | Probucol monoester zur behandlung von kreislauf- und entzündungserkrankungen | |
ATE451930T1 (de) | Verwendung von il-18-hemmern zur behandlung oder prävention von sepsis | |
BR9713673A (pt) | Composições e processos para tratar ou prevenir doenças inflamatórias | |
ES2092460T3 (es) | Composicion dadora de oxido nitrico para el tratamiento de trastornos anales. | |
BR0316203A (pt) | Uso de um agente antialérgico e um esteróide para tratar rinite alérgica | |
DE69927960D1 (de) | Epiallopregnanolon zur behandlung von krankheiten des cns | |
DE69620306D1 (de) | 4-(.Alpha.-hydroxy-.alpha.-aryl-alkylcarbonylamino)-Piperidine zur Behandlung und Prophylaxe von Erkrankungen der Harnwege | |
DE69926665D1 (de) | Azolo-Pyrimidine | |
NO20050718L (no) | Topikal behandling av hudsykdommer | |
DE69929464D1 (de) | Zyklische polyamine zur behandlung der thrombozytopenie | |
ATE138567T1 (de) | Zusammensetzung und verfahren zur behandlung von schmerzvollen entzündlichen oder allergischen erkrankungen | |
ATE453402T1 (de) | Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis | |
ATE473277T1 (de) | Zusammensetzungen und verfahren zur prävention und behandlung von immunvermittelten entzündungskrankheiten | |
ATE541565T1 (de) | Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus | |
DE60144493D1 (de) | Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen | |
DE60122898D1 (de) | Aldosteronantagonist und cyclooxygenase-2 hemmer-kombinationstherapie zur verhinderung oder behandlung von entzündungsverwandten kardiovaskulären krankheiten | |
DE50110552D1 (de) | Verfahren zur behandlung von instabiler angina pectoris | |
MY130725A (en) | Composition and method for treating allergic diseases | |
ATE291425T1 (de) | R-eliprodil zur behandlung von glaucoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |